Compare CNA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNA | GH |
|---|---|---|
| Founded | 1853 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 14.1B |
| IPO Year | N/A | 2018 |
| Metric | CNA | GH |
|---|---|---|
| Price | $46.67 | $101.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 21 |
| Target Price | $53.00 | ★ $82.76 |
| AVG Volume (30 Days) | 468.6K | ★ 2.2M |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $14,850,000,000.00 | $902,569,000.00 |
| Revenue This Year | N/A | $34.72 |
| Revenue Next Year | $21.34 | $26.46 |
| P/E Ratio | $12.73 | ★ N/A |
| Revenue Growth | 5.41 | ★ 30.38 |
| 52 Week Low | $43.29 | $29.91 |
| 52 Week High | $51.34 | $112.43 |
| Indicator | CNA | GH |
|---|---|---|
| Relative Strength Index (RSI) | 58.05 | 55.40 |
| Support Level | $43.80 | $100.21 |
| Resistance Level | $47.04 | $109.59 |
| Average True Range (ATR) | 0.70 | 4.22 |
| MACD | 0.01 | -1.65 |
| Stochastic Oscillator | 82.54 | 13.51 |
CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.